Comparison 6. Transfusion‐dependent thalassemia: deferasirox + deferoxamine vs deferoxamine.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mortality at any time point	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
1.1 at 12 months	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Neutrophil (µg/L): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 ALT (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4 AST (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
5 Serum ferritin: mean at end of study (ng/mL)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
6 Discontinuations	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7 Haemoglobin (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 ALP (g/dL): mean at end of study	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected